drugset / Trial / NCT00080756
Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease
Phase 2
Active not recruiting
11 enrolled
City of Hope Medical Center
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelPrevention
Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Deslorelin combined with low-dose add-back estradiol and testosterone (given to replace hormones suppressed by deslorelin) may be effective in preventing breast cancer in at-risk women. PURPOSE: This phase II trial is studying how well giving deslorelin together with estradiol and testosterone works in preventing breast cancer in premenopausal women who are at high risk for this disease.
Timeline
- Start
- 2004-03-11
- Primary completion
- 2024-09-15
- Completion
- 2024-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deslorelin | Protein / enzyme biologic | 1 mg | Intranasal |
| Subject | Estradiol | Other / unclassified | 0.35 mg | Intranasal |
| Subject | Testosterone | Small molecule | 0.275 mg | Intranasal |